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Abstract
Background: Skeletal muscle wasting is a hallmark of Huntington’s disease (HD). However, data on myocellular
characteristics and myofiber remodeling in HD patients are scarce. We aimed at gaining insights into myocellular
characteristics of HD patients as compared to healthy controls at rest and after a period of increased skeletal
muscle turnover.
Methods: Myosin heavy chain (MyHC)-specific cross-sectional area, satellite cell content, myonuclear number,
myonuclear domain, and muscle fiber type distribution were determined from vastus lateralis muscle biopsies at
rest and after 26 weeks of endurance training in HD patients and healthy controls.
Results: At the beginning of the study, there were no differences in myocellular characteristics between HD patients
and healthy controls. Satellite cell content per MyHC-1 fiber (P = 0.014) and per MyHC-1 myonucleus (P = 0.006)
increased significantly in healthy controls during the endurance training intervention, whereas it remained constant in
HD patients (P = 0.804 and P = 0.975 for satellite cell content per MyHC-1 fiber and myonucleus, respectively). All further
variables were not altered during the training intervention in HD patients and healthy controls.
Conclusions: Similar skeletal muscle characteristics between HD patients and healthy controls at baseline suggested
similar potential for myofiber remodeling in response to exercise. However, the missing satellite cell response in
MyHC-1 myofibers following endurance training in HD patients points to a potential dysregulation in the exercise-
induced activation and/or proliferation of satellite cells. In the longer-term, impaired myonuclear turnover might be
associated with the clinical observation of skeletal muscle wasting.
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Main text
Huntington’s disease (HD) is a neurodegenerative dis-
order with symptoms encompassing motor, cognitive,
and psychiatric dysfunctions. While the initial research
on this disease focused mainly on the central nervous
system, other organs and tissues, such as skeletal muscle,
have additionally gained attention in the scientific litera-
ture in the past few years. For example, several studies
in HD patients reported energy metabolism dysfunctions
in skeletal muscle [1–4] and skeletal muscle pathology
was well-described in mouse models [5–7]. Because
skeletal muscle wasting is regarded as a hallmark of HD,
skeletal muscle mass was also investigated in recent pub-
lications. In these studies, no differences in whole-body
fat-free mass or lean mass between HD patients and
healthy controls could be detected [8–11]. These find-
ings challenge the notion of skeletal muscle wasting, at
least in early- to mid-stage HD patients. Moreover, data
on muscle fiber cross-sectional areas, satellite cells,
myonuclei, and myofiber remodeling upon exercise in
HD patients remain scarce.
In the current preliminary study, we aimed at gaining
insights into muscle fiber cross-sectional areas, satellite
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cell content, myonuclear content and myonuclear num-
ber of HD patients as compared to healthy controls at
rest and after a period of increased skeletal muscle
turnover. We reanalyzed muscle biopsy samples from a
previous study [12]. Due to limitations in muscle tissue
amount, we were not able to analyze all samples of the
previous study. Muscle samples of nine HD patients
(age: 51.7 ± 7.9 years, height: 1.74 ± 0.05 m, body mass:
75.9 ± 11.2 kg) and ten healthy control participants (age:
50.0 ± 6.7 years, height: 1.79 ± 0.05 m, body mass: 82.8 ±
13.0 kg) could be analyzed and the results thereof are
presented in this report. According to the clinical
a) b)
c) d)
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Fig. 1 Representative images of fiber type-specific analyses of skeletal muscle satellite cell content. a) Myosin heavy chain (MyHC) isoforms
stained as follows: MyHC-1 (red), MyHC-2A (green), MyHC-2X (unstained, black), b) co-occurrence of Pax7+ cell (red) with subsarcolemmal myonucleus
(blue) and cell border line (green), c) merosin staining for cell borders (green), d) subarcolemmal myonuclei (blue), e) Pax7+ cell (red), f) co-occurrence
of Pax7+ cell (red) with subsarcolemmal myonucleus (blue)
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Fig. 2 (See legend on next page.)
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assessments, the HD patients were classified as early-
and intermediate-stage of disease. Myosin heavy chain
(MyHC)-specific cross-sectional area, satellite cell con-
tent, myonuclear number, and myonuclear domain were
determined from vastus lateralis muscle biopsies at rest
and after 26 weeks of endurance training in HD patients
and healthy controls (Fig. 1). An additional muscle
biopsy sample was obtained from HD patients 26 weeks
before beginning of the training intervention to assess
alterations due to the natural disease progress.
At the beginning of the study, there were no differ-
ences in myocellular characteristics between HD patients
and healthy controls (Fig. 2). Satellite cell content per
MyHC-1 fiber (P = 0.014) and per MyHC-1 myonucleus
(P = 0.006) increased significantly in healthy controls
during the endurance training intervention, whereas it
remained constant in HD patients (P = 0.804 and P =
0.975 for satellite cell content per MyHC-1 fiber and
myonucleus, respectively). There was a significant group
x time interaction for satellite cells per MyHC-1 myonu-
cleus (P = 0.045). All further variables were not altered
during the training intervention in HD patients and
healthy controls. During the natural course observation
period in HD patients, there were no fiber type-specific
alterations in any variable.
Similar skeletal muscle characteristics between HD
patients and healthy controls at baseline suggested
similar potential for myofiber remodeling in response to
exercise and indicated that these characteristics are not
affected by pathological processes in the early- and mid-
stage of the disease. This observation was further
supported by the constant myocellular characteristics
during the half-year natural course observation period.
However, the missing satellite cell response in MyHC-1
myofibers following a half-year endurance training
intervention in HD patients pointed to a potential
dysregulation in the exercise-induced activation and/or
proliferation of satellite cells. Due to the absence of new
genetic material to replace damaged DNA, tissue re-
modeling might be impaired in subsequent years,
resulting in an attenuation of myofiber regeneration.
In conclusion, our result points to impaired myonuc-
lear turnover in HD patients that might be associated
with the clinical observation of skeletal muscle
wasting in the longer-term.
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